The KRAS mutational spectrum and its clinical implications in pancreatic cancer.

Journal

Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617

Informations de publication

Date de publication:
20 Aug 2024
Historique:
received: 31 07 2024
revised: 01 08 2024
accepted: 01 08 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 30 8 2024
Statut: aheadofprint

Résumé

In this issue of Cancer Cell, McIntyre et al. show that specific mutations in the KRAS proto-oncogene shape clinical progression of pancreatic ductal adenocarcinoma (PDAC). Importantly, they find that the KRAS

Identifiants

DOI: 10.1016/j.ccell.2024.08.001 PMID: 39214093
pubmed: 39214093
pii: S1535-6108(24)00293-9
doi: 10.1016/j.ccell.2024.08.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Luigi Perelli (L)

Department of Genomic Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: lperelli@mdanderson.org.

Giannicola Genovese (G)

Department of Genomic Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

Giulio F Draetta (GF)

Department of Genomic Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: gdraetta@mdanderson.org.

Classifications MeSH